Lenalidomide Wockhardt Uk

Lenalidomide, the active ingredient in Lenalidomide Wockhardt Uk, is an immunomodulatory agent presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Wockhardt Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is an immunomodulatory antineoplastic agent used in hematologic malignancies.

- Multiple Myeloma: improves progression‑free survival and overall response rates. - Myelodysplastic Syndromes: reduces transfusion dependence and improves peripheral blood counts. - Mantle Cell Lymphoma: induces tumor regression and prolongs remission periods.

Lenalidomide may cause a range of adverse reactions, some of which are frequent and others that are uncommon but potentially serious.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet count leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Lenalidomide requires careful monitoring and adherence to safety measures.

- Pregnancy Risk: avoid use during pregnancy; effective contraception is required. - Thromboembolic Prophylaxis: consider anticoagulation in high‑risk patients. - Hematologic Monitoring: regular blood counts to detect neutropenia or thrombocytopenia. - Renal Impairment: dose adjustment may be needed in reduced kidney function. - Drug Interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure. - Anticoagulants: increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - Immunosuppressants: may enhance infection risk. - P-glycoprotein substrates: potential alteration of plasma levels. - NSAIDs: may exacerbate gastrointestinal irritation. - Vaccines: live vaccines should be avoided due to immunomodulation.